The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

Clinical and Translational Oncology

Volumn 18, Issue 9, 2016, Pages 915-924

  Mlak, R ^a   Krawczyk, P ^a   Ciesielka, M ^a   Koziol P ^a   Homa, I ^a   Powrozek T ^a   Prendecka, M ^a   Milanowski, J ^a   Malecka Massalska T ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer; Platinum compounds; RRM1

Indexed keywords

DOCETAXEL; ERLOTINIB; GEMCITABINE; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM DERIVATIVE; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CYTODIAGNOSIS; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOLECULAR PHYLOGENY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RRM1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TUMOR SUPPRESSOR PROTEINS;

EID: 84949526321     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1461-1     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013;63:11–30.
2. ®) Non-Small Cell Lung Cancer version 1.2015 (2015) http://www.nccn.org. Accessed 25 June 2015.
3. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014;15:173–81.
4. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer. 2014;15:21–51.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
6. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.
7. Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrózek T, Lewandowska MA, Limon J, et al. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. J Cancer Res Clin Oncol. 2015;141(1):61–8. doi:10.1007/s00432-014-1789-x.
8. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–62.
9. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48:961–73.
10. Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012;118:2525–31.
11. Zhang Q, Zhu X, Zhang L, Sun S, Huang J, Lin Y. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2014;74:839–46.
12. Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, et al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer. 2013;82(2):288–93.
13. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5(1):19–33.
14. Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol. 2003;30(Suppl 10):19–25.
15. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005;47:183–92.
16. Feng JF, Wu JZ, Hu SN, Gao CM, Shi MQ, Lu ZH, et al. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer. 2009;66:344–9.
17. Dong S, Guo AL, Chen ZH, Wang Z, Zhang XC, Huang Y, et al. RRM1 single nucleotide polymorphism—37C > A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol. 2010;3:10.
18. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, Zhou S, et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol. 2012;14(3):207–13.
19. Deng JH, Deng J, Shi DH, Ouyang XN, Niu PG. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients. Clin Transl Oncol. 2015 (Epub ahead of print).
20. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res. 2008;14(10):3083–8.
21. Lin L, Liu X, Song S, Wang S. A study on the relationship between RRM1 single nucleotide polymorphisms and clinical characteristics in lung cancer patients. Zhongguo Fei Ai Za Zhi. 2008;11(6):784–8.
22. Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, et al. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep. 2013;30(5):2385–98.
23. Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 2011;71(2):191–8.
24. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.
25. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol. 2011;6(12):2018–26.
26. Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, et al. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol. 2011;6(8):1320–9.